Cardiovascular disease and ACE inhibitors: focusing on enalapril
Abstract
Enalapril is one of the best-studied ACE inhibitors, demonstrating high effectiveness in treating arterial hypertension, chronic heart failure, and left ventricular dysfunction, including that after myocardial infarction. One of the best enalapril generics is Berlipril® – an ACE inhibitor with unique structure, providing 100% bioavailability of the active agent.
About the Author
G. A. Baryshnikova
Teaching and Research Medical Center, RF President Administration, Moscow
Russian Federation
Russian Federation
References
1. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004; 30(6): 487-96.
2. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348(7): 583-92.
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302.
5. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
6. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361(9372): 1843-8.
7. Loeb HS, Johnson G, Henrick A, et al. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V- HeFT VA Cooperative Studies Group. Circulation 1993; 87(6 Suppl): VI78-87.
8. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273(18): 1450-6.
9. Luzier AB, Forrest A, Adelman M, et al. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998; 82(4): 465-9.
10. Foy SG, Crozier IG, Turner JG, et al. Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the «PRACTICAL» study). Am J Cardiol 1994; 73(16): 1180-6.
11. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156(3): 286-9.
12. Шестакова М.В. Ингибиторы ангиотензин-превращающего фермента и патология почек: непревзойденный нефропротективный эффект. Cons Med 2002; 4(3): 134-6.
13. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107(9): 1291-6.
14. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril reduces the incidence of atrial fibrillation in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107(9): 2926-31.
15. Tabacova SA, Kimmel CA. Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity. A review; Reproductive Toxicology 2001; 15: 467-78.
Review
For citations:
Baryshnikova G.A. Cardiovascular disease and ACE inhibitors: focusing on enalapril. Cardiovascular Therapy and Prevention. 2007;6(6):69-74. (In Russ.)
Views:
992
Email this article 
